The UK government said on Friday it had signed a contract to buy an additional 90 million doses of the coronavirus vaccine, as the country races to secure supplies of test shots to fight the pandemic.
Under the new principle agreements, US drug developer Novavax NVAX,
will deliver 60 million doses of its coronavirus vaccine to UK Janssen Pharmaceutical Company, a division of Johnson & Johnson JNJ,
will give the UK 30 million doses of its candidate.
With today’s announcement, the UK has now secured access to six different candidates, across four different vaccines, bringing the country’s potential stockpile to 340 million doses – one among the largest sources in the world. This is enough for five doses per person.
“The government’s strategy to build a promising portfolio of vaccine candidates will ensure we have the best possible chance of finding an effective vaccine,” said Alok Sharma, Wang’s business secretary. UK said in a statement. “Today’s agreements will not only benefit the people of the UK, but also ensure fair and equal access to vaccines worldwide, potentially protecting hundreds of millions of lives. network. ” he added.
If the vaccine is safe and successful in clinical trials, the government said, both of these vaccines could be delivered to the UK by mid-2021.
Read:The UK contracts with BioNTech, Pfizer and Valneva for the COVID-19 vaccine
The deals come when the European Commission said on Friday that it had reached an agreement with AstraZeneca AZN listed in the FTSE-100,
to purchase at least 300 million doses of the potential COVID-19 vaccine.
On Friday, Novavax said it would deliver 60 million doses of the coronavirus vaccine to the UK as early as the first quarter of 2021. As part of the agreement, the UK will fund a test run. a final stage experience for Novavax NVAX,
Vaccine candidate to evaluate the effectiveness of the vaccine on the national population.
The trial, scheduled to begin in Q3 2020, will be a study of approximately 9,000 adults aged 18 to 85 years to protect against symptomatic COVID-19 as well as evaluate the response of symptoms. antibodies and T cells, Novavax said in a statement.
Read:Novavax says its COVID-19 vaccine shows promising results in the initial study
Kate Bingham, president of the UK government’s Vaccine Task Force, said it is encouraging that the recent Novavax clinical data shows their vaccines trigger a higher immune response than in other the patient was cured.
“We believe that Novavax has a highly innovative vaccine that could be the first of its kind in protein-based vaccine choices. We are delighted to partner with them and with global organizations like CEPI [Coalition for Epidemic Preparedness Innovations] to strengthen our shared commitment to ensuring vaccine access globally, ”she said.
Separately, Johnson & Johnson said their Belgian subsidiary Janssen will provide the UK government with a candidate called Ad26.COV2-S in an initial sale of 30 million doses on a non-profit basis. Profit for use in a pandemic emergency. The UK has an option to purchase an additional 22 million doses.
The ministers also agreed in principle to co-finance a global clinical study on Janssen vaccine. The next phase of clinical trials is expected to begin later this year to see if giving the two candidate doses of the candidate vaccine provides long-term protection against the coronavirus. or not.
Read:Johnson & Johnson began testing COVID-19 vaccine after inducing an immune response in primates.
In July, the government also said it had secured early access to 90 million doses of the two COVID-19 vaccines that could be developed by a collaboration between German BioNTech BNTX,
and US drug manufacturer Pfizer PFE,
as well as one of the French group Valneva. In the same month, GlaxoSmithKline GSK,
said it bought a stake in German vaccine maker CureVac.
The UK government previously announced an agreement with AstraZeneca for the drug maker to produce 100 million potential doses of the vaccine that is being developed in partnership with Oxford University.
Novavax said it will work with Fujifilm Diosynth Biotechnologies to produce the antigenic composition of the coronavirus vaccine candidate, NVX-CoV2373, from Billingham, Stockton-on-Tees in the UK, to produce 180 million doses of the vaccine. – Please do this every year.